Maren I Blonk1, Angela P H Colbers1, Carmen Hidalgo-Tenorio2, Kabamba Kabeya3, Katharina Weizsäcker4, Annette E Haberl5, José Moltó6, David A Hawkins7, Marchina E van der Ende8, Andrea Gingelmaier9, Graham P Taylor10, Jelena Ivanovic11, Carlo Giaquinto12, David M Burger1. 1. Radboud University Medical Center, Nijmegen, The Netherlands. 2. Hospital Universitario Virgen de las Nieves, Granada, Spain. 3. Saint-Pierre University Hospital, Brussels, Belgium. 4. Klinik für Geburtsmedizin, Charité Universitätsmedizin, Berlin. 5. Universitätsklinikum Frankfurt, Medizinische Klinik II, Germany. 6. Hospital Universitari Germans Trias i Pujol, 'Lluita contra la Sida' Foundation, Badalona, Spain. 7. Chelsea and Westminster Hospital, London, United Kingdom. 8. Erasmus Medical Center, Rotterdam, The Netherlands. 9. Klinikum der Universität München, Frauenklinik Innenstadt, Munich, Germany. 10. Imperial College Healthcare NHS Trust, London, United Kingdom. 11. National Institute for Infectious Diseases 'L. Spallanzani,' Rome. 12. University of Padua, Italy.
Abstract
BACKGROUND: The use of raltegravir in human immunodeficiency virus (HIV)-infected pregnant women is important in the prevention of mother-to-child HIV transmission, especially in circumstances when a rapid decline of HIV RNA load is warranted or when preferred antiretroviral agents cannot be used. Physiological changes during pregnancy can reduce antiretroviral drug exposure. We studied the effect of pregnancy on the pharmacokinetics of raltegravir and its safety and efficacy in HIV-infected pregnant women. METHODS: An open-label, multicenter, phase 4 study in HIV-infected pregnant women receiving raltegravir 400 mg twice daily was performed (Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women Network). Steady-state pharmacokinetic profiles were obtained in the third trimester and postpartum along with cord and maternal delivery concentrations. Safety and virologic efficacy were evaluated. RESULTS: Twenty-two patients were included, of which 68% started raltegravir during pregnancy. Approaching delivery, 86% of the patients had an undetectable viral load (<50 copies/mL). None of the children were HIV-infected. Exposure to raltegravir was highly variable. Overall area under the plasma concentration-time curve (AUC) and plasma concentration at 12 hours after intake (C12h) plasma concentrations in the third trimester were on average 29% and 36% lower, respectively, compared with postpartum: Geometric mean ratios (90% confidence interval) were 0.71 (.53-.96) for AUC0-12h and 0.64 (.34-1.22) for C12h. The median ratio of raltegravir cord to maternal blood was 1.21 (interquartile range, 1.02-2.17; n = 9). CONCLUSIONS: Raltegravir was well tolerated during pregnancy. The pharmacokinetics of raltegravir showed extensive variability. The observed mean decrease in exposure to raltegravir during third trimester compared to postpartum is not considered to be of clinical importance. Raltegravir can be used in standard dosages in HIV-infected pregnant women. CLINICAL TRIALS REGISTRATION: NCT00825929.
BACKGROUND: The use of raltegravir in human immunodeficiency virus (HIV)-infected pregnant women is important in the prevention of mother-to-childHIV transmission, especially in circumstances when a rapid decline of HIV RNA load is warranted or when preferred antiretroviral agents cannot be used. Physiological changes during pregnancy can reduce antiretroviral drug exposure. We studied the effect of pregnancy on the pharmacokinetics of raltegravir and its safety and efficacy in HIV-infected pregnant women. METHODS: An open-label, multicenter, phase 4 study in HIV-infected pregnant women receiving raltegravir 400 mg twice daily was performed (Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women Network). Steady-state pharmacokinetic profiles were obtained in the third trimester and postpartum along with cord and maternal delivery concentrations. Safety and virologic efficacy were evaluated. RESULTS: Twenty-two patients were included, of which 68% started raltegravir during pregnancy. Approaching delivery, 86% of the patients had an undetectable viral load (<50 copies/mL). None of the children were HIV-infected. Exposure to raltegravir was highly variable. Overall area under the plasma concentration-time curve (AUC) and plasma concentration at 12 hours after intake (C12h) plasma concentrations in the third trimester were on average 29% and 36% lower, respectively, compared with postpartum: Geometric mean ratios (90% confidence interval) were 0.71 (.53-.96) for AUC0-12h and 0.64 (.34-1.22) for C12h. The median ratio of raltegravir cord to maternal blood was 1.21 (interquartile range, 1.02-2.17; n = 9). CONCLUSIONS:Raltegravir was well tolerated during pregnancy. The pharmacokinetics of raltegravir showed extensive variability. The observed mean decrease in exposure to raltegravir during third trimester compared to postpartum is not considered to be of clinical importance. Raltegravir can be used in standard dosages in HIV-infected pregnant women. CLINICAL TRIALS REGISTRATION: NCT00825929.
Authors: Lisa Rahangdale; Jordan Cates; JoNell Potter; Martina L Badell; Dominika Seidman; Emilly S Miller; Jenell S Coleman; Gweneth B Lazenby; Judy Levison; William R Short; Sigal Yawetz; Andrea Ciaranello; Elizabeth Livingston; Lunthita Duthely; Bassam H Rimawi; Jean R Anderson; Elizabeth M Stringer Journal: Am J Obstet Gynecol Date: 2016-03 Impact factor: 8.661
Authors: Bassam H Rimawi; Erica Johnson; Augustine Rajakumar; Sijia Tao; Yong Jiang; Scott Gillespie; Raymond F Schinazi; Mark Mirochnick; Martina L Badell; Rana Chakraborty Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Nikki Mulligan; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Alice Stek; Emily Barr; Shelley L Buschur; Edward P Acosta; Elizabeth Smith; Nahida Chakhtoura; Sandra Burchett; Mark Mirochnick Journal: AIDS Date: 2018-03-27 Impact factor: 4.177
Authors: Esaú C João; R Leavitt Morrison; David E Shapiro; Nahida Chakhtoura; Maria Isabel S Gouvèa; Maria de Lourdes B Teixeira; Trevon L Fuller; Blandina T Mmbaga; James S Ngocho; Boniface N Njau; Avy Violari; Ruth Mathiba; Zaakirah Essack; Jose Henrique S Pilotto; Luis Felipe Moreira; Maria Jose Rolon; Pedro Cahn; Sinart Prommas; Timothy R Cressey; Kulkanya Chokephaibulkit; Peerawong Werarak; Lauren Laimon; Roslyn Hennessy; Lisa M Frenkel; Patricia Anthony; Brookie M Best; George K Siberry; Mark Mirochnick Journal: Lancet HIV Date: 2020-05 Impact factor: 12.767
Authors: Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann Journal: Clin Pharmacokinet Date: 2020-11 Impact factor: 6.447